Immunogenicity of alternative and reduced immunization schedules using the thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae.

Trial Profile

Immunogenicity of alternative and reduced immunization schedules using the thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Acronyms PIM studie
  • Most Recent Events

    • 04 Sep 2013 Results published in JAMA: the Journal of the American Medical Association.
    • 16 Dec 2012 Status changed from planning to completed as reported by Netherlands Trial Register.
    • 17 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top